RS56285B1 - C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae) - Google Patents

C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae)

Info

Publication number
RS56285B1
RS56285B1 RS20170802A RSP20170802A RS56285B1 RS 56285 B1 RS56285 B1 RS 56285B1 RS 20170802 A RS20170802 A RS 20170802A RS P20170802 A RSP20170802 A RS P20170802A RS 56285 B1 RS56285 B1 RS 56285B1
Authority
RS
Serbia
Prior art keywords
hae
prevention
treatment
hereditary angioedema
inh
Prior art date
Application number
RS20170802A
Other languages
English (en)
Inventor
Cynthia Gallagher
Stephen Ruddy
Mark Cornell Manning
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS56285(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of RS56285B1 publication Critical patent/RS56285B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RS20170802A 2013-03-15 2014-03-17 C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae) RS56285B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
EP14762343.3A EP2968434B1 (en) 2013-03-15 2014-03-17 C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).

Publications (1)

Publication Number Publication Date
RS56285B1 true RS56285B1 (sr) 2017-12-29

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20170802A RS56285B1 (sr) 2013-03-15 2014-03-17 C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae)
RS20190198A RS58351B1 (sr) 2013-03-15 2014-03-17 C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20190198A RS58351B1 (sr) 2013-03-15 2014-03-17 C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Country Status (30)

Country Link
US (9) US9616111B2 (sr)
EP (3) EP3290046B1 (sr)
JP (9) JP6184581B2 (sr)
KR (4) KR102579789B1 (sr)
CN (2) CN111529708A (sr)
AU (3) AU2014232912A1 (sr)
BR (1) BR112015023207A8 (sr)
CA (2) CA3054718A1 (sr)
CY (2) CY1119419T1 (sr)
DE (1) DE202014011208U1 (sr)
DK (2) DK2968434T3 (sr)
EA (1) EA201591278A1 (sr)
ES (2) ES2639833T3 (sr)
GB (1) GB2530921B (sr)
HK (2) HK1220403A1 (sr)
HR (2) HRP20171269T1 (sr)
HU (2) HUE036224T2 (sr)
IL (2) IL241549B (sr)
LT (2) LT3290046T (sr)
ME (2) ME03326B (sr)
MX (3) MX2020004724A (sr)
NZ (2) NZ710730A (sr)
PL (2) PL2968434T3 (sr)
PT (2) PT2968434T (sr)
RS (2) RS56285B1 (sr)
SG (2) SG11201507616VA (sr)
SI (2) SI3290046T1 (sr)
TR (1) TR201900319T4 (sr)
WO (1) WO2014145519A2 (sr)
ZA (3) ZA201507604B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111529708A (zh) 2013-03-15 2020-08-14 夏尔维洛药品公司 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法
LT3071219T (lt) * 2013-11-22 2019-01-10 Shire Viropharma Incorporated Antikūnų sukelto atmetimo gydymo būdai organų transplantacijos pacientuose su c1 esterazės inhibitoriumi
EP3258911A1 (en) * 2015-02-20 2017-12-27 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
EP3302540A4 (en) * 2015-05-28 2018-08-22 Cornell University Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
BR112018010160A8 (pt) * 2015-11-19 2019-02-26 Shire Human Genetic Therapies inibidor da c1 esterase humana recombinante e usos do mesmo
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) * 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
US20200069780A1 (en) 2017-05-16 2020-03-05 Octapharma Ag C1-esterase inhibitor preparation
CN111818938A (zh) 2018-02-28 2020-10-23 法明知识产权股份有限公司 先兆子痫的治疗和预防
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210024048A (ko) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 및 치료법
WO2019245039A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 感染性免疫寛容を惹起するための組成物
MX2020014101A (es) 2018-06-22 2021-05-27 Junten Bio Co Ltd Anticuerpo que induce tolerancia inmunitaria, linfocito inducido, y agente de terapia celular/metodo terapeutico que usa linfocitos inducidos.
JPWO2021124793A1 (sr) * 2019-12-16 2021-06-24
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CA3225079A1 (en) 2021-07-09 2023-01-12 Bruno Giannetti Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE69429816T2 (de) 1993-09-01 2002-09-19 Sanquin Bloedvoorziening C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
PT1252184E (pt) 2000-01-31 2008-04-15 Pharming Intellectual Pty Bv Inibidor humano c1 produzido no leite de mamíferos transgénicos
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
USRE43691E1 (en) 2003-05-16 2012-09-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP2529746A1 (en) 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.
KR101508668B1 (ko) 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
ES2753183T3 (es) 2007-02-12 2020-04-07 Csl Behring Gmbh Aplicación terapéutica de inhibidores de la proteasa de serina de tipo Kazal
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
BR112012008970A2 (pt) 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
EP2758076B1 (en) 2011-09-24 2018-12-12 CSL Behring GmbH Combination therapy using immunoglobulin and c1-inhibitor
US9452203B2 (en) 2011-12-22 2016-09-27 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
JP2015512370A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１−阻害剤のポリマーコンジュゲート
EP2972375A2 (en) 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
CN111529708A (zh) * 2013-03-15 2020-08-14 夏尔维洛药品公司 用于预防和治疗与c1酯酶抑制剂缺乏相关的病症的c1-inh组合物和方法

Also Published As

Publication number Publication date
HUE036224T2 (hu) 2018-06-28
GB201519921D0 (en) 2015-12-23
ZA201806793B (en) 2020-01-29
US20180153972A1 (en) 2018-06-07
ME02865B (me) 2018-04-20
US20160015795A1 (en) 2016-01-21
JP2018119000A (ja) 2018-08-02
ZA201507604B (en) 2018-05-30
JP2019073545A (ja) 2019-05-16
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
NZ751555A (en) 2021-07-30
WO2014145519A2 (en) 2014-09-18
GB2530921B (en) 2017-09-20
US11534482B2 (en) 2022-12-27
SG10201707598QA (en) 2017-10-30
CY1119419T1 (el) 2018-03-07
HK1250912B (zh) 2020-01-10
KR20220070049A (ko) 2022-05-27
ES2639833T3 (es) 2017-10-30
US20200261556A1 (en) 2020-08-20
SG11201507616VA (en) 2015-10-29
ZA201706929B (en) 2019-05-29
MX2015011281A (es) 2016-03-03
AU2018229558B2 (en) 2020-03-05
ME03326B (me) 2019-10-20
PL3290046T3 (pl) 2019-05-31
ES2713004T3 (es) 2019-05-17
US9616111B2 (en) 2017-04-11
MX2020004724A (es) 2022-01-18
BR112015023207A2 (pt) 2017-11-21
HRP20190270T1 (hr) 2019-04-05
JP2016516073A (ja) 2016-06-02
AU2014232912A1 (en) 2015-09-03
TR201900319T4 (tr) 2019-02-21
JP6473534B2 (ja) 2019-02-20
PT3290046T (pt) 2019-02-18
HRP20171269T1 (hr) 2017-11-03
JP6473535B2 (ja) 2019-02-20
JP2017105847A (ja) 2017-06-15
LT2968434T (lt) 2017-09-25
US20180085441A1 (en) 2018-03-29
SI3290046T1 (sl) 2019-04-30
DE202014011208U1 (de) 2018-08-23
US20190160158A1 (en) 2019-05-30
GB2530921A (en) 2016-04-06
KR20150135242A (ko) 2015-12-02
CA2904543A1 (en) 2014-09-18
JP6473536B2 (ja) 2019-02-20
CA3054718A1 (en) 2014-09-18
IL276153B (en) 2022-06-01
WO2014145519A3 (en) 2014-12-31
LT3290046T (lt) 2019-03-12
AU2018229558A1 (en) 2018-10-04
US10080788B2 (en) 2018-09-25
SI2968434T1 (sl) 2017-11-30
EA201591278A1 (ru) 2016-03-31
US20170224788A1 (en) 2017-08-10
EP3290046A1 (en) 2018-03-07
HUE041837T2 (hu) 2019-05-28
CA2904543C (en) 2019-10-08
KR102430453B1 (ko) 2022-08-05
US10105423B2 (en) 2018-10-23
EP2968434A2 (en) 2016-01-20
JP6184581B2 (ja) 2017-08-23
EP2968434B1 (en) 2017-06-28
JP2018119001A (ja) 2018-08-02
DK2968434T3 (en) 2017-09-11
PL2968434T3 (pl) 2018-01-31
JP2021088599A (ja) 2021-06-10
MX2021011946A (es) 2021-11-17
JP6877472B2 (ja) 2021-05-26
US20180110844A1 (en) 2018-04-26
JP6877471B2 (ja) 2021-05-26
CN105517559A (zh) 2016-04-20
JP2018119002A (ja) 2018-08-02
JP2019073546A (ja) 2019-05-16
IL276153A (en) 2020-09-30
JP6422520B2 (ja) 2018-11-14
EP2968434A4 (en) 2016-03-02
EP3508213A1 (en) 2019-07-10
KR20210129267A (ko) 2021-10-27
AU2020203183B2 (en) 2022-06-02
JP6877470B2 (ja) 2021-05-26
CN111529708A (zh) 2020-08-14
BR112015023207A8 (pt) 2018-01-23
HK1220403A1 (zh) 2017-05-05
CY1121653T1 (el) 2020-07-31
KR102579789B1 (ko) 2023-09-15
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
DK3290046T3 (en) 2019-03-18
US11364288B2 (en) 2022-06-21
IL241549B (en) 2020-08-31
KR20210021146A (ko) 2021-02-24
US20190160157A1 (en) 2019-05-30
JP2019073544A (ja) 2019-05-16
AU2020203183A1 (en) 2020-06-04
PT2968434T (pt) 2017-09-18
RS58351B1 (sr) 2019-03-29
EP3290046B1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
RS56285B1 (sr) C1-inh kompozicije za upotrebu u prevenciji i lečenju naslednog angioedema (hae)
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2814317A4 (en) FUNGICIDAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND NAILS
HK1206266A1 (en) Methods and compositions for the prevention and treatment neuropathy
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
HK1207289A1 (en) Composition for prevention of vasoactivity in the treatment of blood loss and anemia
HK1206598A1 (en) Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
AU2013904048A0 (en) Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla